What is the science behind the tri-platform approach?

It integrates low-temperature plasma to target cell membranes, ultrasound for deep-penetration, and microbubbles to facilitate delivery [3, 4].

Does this treatment damage the healthy surrounding skin?

No. Low-temperature cold plasma is designed to selectively target fungal pathogens while keeping the surrounding healthy skin tissue completely safe [3, 4].

What is the timeline for availability?

The device is currently in development stages targeting FDA clearance by 2028.

How does this technology improve absorption?

Microbubbles generate localized vibrations to create temporary pathways through the nail.

Does this treatment cause systemic side effects?

No. Localized dual-action therapy acts directly on the nail bed, avoiding the liver.

When is this device expected to launch?

Jubilee Biomedical is actively progressing development, targeting FDA clearance in 2028.

Reimagining Nail Restoration

Combining Cold Plasma and Ultrasound

Jubilee Biomedical

Next-Generation Medical Aesthetics

Disrupting Fungal Membranes

Targeted low-temperature cold plasma

Transdermal Wave Delivery

Microbubbles and deep ultrasound

Zero Chemical Burden

Bypassing systemic oral toxicity

Regulatory Milestone Roadmap

Targeting FDA clearance in 2028

Three Integrated Platforms

Consolidated clinical precision

Connect with Jubilee

Partnering for the future of non-invasive clinical care

Frequently Asked Questions

What is the science behind the tri-platform approach?: It integrates low-temperature plasma to target cell membranes, ultrasound for deep-penetration, and microbubbles to facilitate delivery [3, 4].
Does this treatment damage the healthy surrounding skin?: No. Low-temperature cold plasma is designed to selectively target fungal pathogens while keeping the surrounding healthy skin tissue completely safe [3, 4].
What is the timeline for availability?: The device is currently in development stages targeting FDA clearance by 2028.
How does this technology improve absorption?: Microbubbles generate localized vibrations to create temporary pathways through the nail.
Does this treatment cause systemic side effects?: No. Localized dual-action therapy acts directly on the nail bed, avoiding the liver.
When is this device expected to launch?: Jubilee Biomedical is actively progressing development, targeting FDA clearance in 2028.